Yes, this patient is eligible for Foundayo
A patient with BMI 28.1 kg/m² and dyslipidemia meets FDA-approved criteria for Foundayo (orforglipron) and should be considered an appropriate candidate for this medication. 1
Eligibility Criteria
According to the FDA label, Foundayo is approved for adults with:
- BMI ≥27 kg/m² with at least one weight-related comorbid condition, OR
- BMI ≥30 kg/m² 1
Your patient meets the first criterion with:
- BMI of 28.1 kg/m² (exceeds the 27 threshold)
- Dyslipidemia (qualifies as a weight-related comorbidity)
This eligibility framework is consistently supported across multiple clinical practice guidelines. The AGA guidelines 2 and ADA guidelines 3, 4 all recommend pharmacotherapy for obesity when BMI ≥27 kg/m² with weight-related comorbidities such as dyslipidemia, hypertension, or type 2 diabetes.
Clinical Trial Evidence Supporting Use
The FDA approval was based on trials that specifically included patients with dyslipidemia. In the pooled safety analysis of Trials 1 and 2, 49% of participants had dyslipidemia at baseline—nearly identical to your patient's profile 1. The mean baseline BMI was 36.5 kg/m², but the trials enrolled patients with BMI ≥27 kg/m² with comorbidities, confirming your patient falls within the studied population.
Important Clinical Considerations
Cardiovascular Benefits
Dyslipidemia management is particularly relevant here. Post-hoc analysis of the ATTAIN-1 trial demonstrated that orforglipron significantly reduced predicted 10-year cardiovascular disease risk using validated prediction models (Framingham and PREVENT), with absolute CVD risk reductions of -0.6% to -1.0% versus placebo 5. This suggests potential cardiovascular benefit beyond weight loss alone.
Safety Profile in This Population
The clinical trials showed that patients with dyslipidemia tolerated Foundayo well. Common adverse events were predominantly gastrointestinal (nausea 26-35%, constipation 20-27%, diarrhea 21-25%) 1. Importantly, there were no specific contraindications related to dyslipidemia, and lipid disorders do not appear in the warnings or precautions sections of the FDA label.
Practical Implementation
Foundayo must be used as adjunct therapy—not as monotherapy. The FDA approval specifically requires combination with:
- Reduced-calorie diet
- Increased physical activity 1
This aligns with guideline recommendations that emphasize pharmacotherapy should never replace lifestyle modification but rather augment it 6, 2, 4.
Dosing approach: Start at 5.5 mg once daily and titrate based on tolerability and efficacy, with dose escalation options to 9 mg and 17.2 mg 1. The dose-response data shows progressive improvements in weight loss and metabolic parameters at higher doses 7, 8.
Common Pitfalls to Avoid
- Don't delay treatment waiting for BMI ≥30: Your patient already meets criteria at BMI 28.1 with dyslipidemia
- Don't prescribe without lifestyle intervention: The medication is FDA-approved only as adjunct to diet and exercise
- Monitor for GI side effects: 60-69% of patients experience GI adverse reactions, though most are mild-to-moderate 1
- Assess response at 12 weeks: If <5% weight loss by 3 months, consider dose escalation or alternative therapy 2, 3
The South and Southeast Asia consensus also supports pharmacotherapy at BMI ≥27 kg/m² with complications, though they note that in countries defining obesity at BMI ≥25 kg/m², case-by-case consideration may be appropriate for BMI 25-26.9 kg/m² 6. Your patient at BMI 28.1 is well above any threshold requiring special consideration.